Literature DB >> 25389917

Vincristine and Dactinomycin in Infantile Myofibromatosis With a Review of Treatment Options.

Meaghann S Weaver1, Fariba Navid, Alison Huppmann, Holly Meany, Anne Angiolillo.   

Abstract

Although solitary presentations of infantile myofibromatosis tend toward spontaneous regression, multicentric forms fare worse. Previous case reports have depicted observation, surgical resection, and systemic therapies as treatment options. This paper reports well-tolerated, successful outcomes in a series of patients with high-risk infantile myofibromatosis in need of life-sustaining interventions treated with a combination of vincristine and dactinomycin. The clinical presentation, pathology, and radiographic findings are described.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25389917     DOI: 10.1097/MPH.0000000000000286

Source DB:  PubMed          Journal:  J Pediatr Hematol Oncol        ISSN: 1077-4114            Impact factor:   1.289


  6 in total

1.  Novel PDGFRB rearrangement in multifocal infantile myofibromatosis is tumorigenic and sensitive to imatinib.

Authors:  Mohammed Hassan; Erin Butler; Raphael Wilson; Angshumoy Roy; Yanbin Zheng; Priscilla Liem; Dinesh Rakheja; Dean Pavlick; Lauren L Young; Mark Rosenzweig; Rachel Erlich; Siraj M Ali; Patrick J Leavey; D Williams Parsons; Stephen X Skapek; Theodore W Laetsch
Journal:  Cold Spring Harb Mol Case Stud       Date:  2019-10-23

2.  Aggressive infantile myofibromatosis with intestinal involvement.

Authors:  Tristan Römer; Norbert Wagner; Till Braunschweig; Robert Meyer; Miriam Elbracht; Udo Kontny; Olga Moser
Journal:  Mol Cell Pediatr       Date:  2021-06-16

3.  Functional disruption of the Golgi apparatus protein ARF1 sensitizes MDA-MB-231 breast cancer cells to the antitumor drugs Actinomycin D and Vinblastine through ERK and AKT signaling.

Authors:  Charlotte Luchsinger; Marcelo Aguilar; Patricia V Burgos; Pamela Ehrenfeld; Gonzalo A Mardones
Journal:  PLoS One       Date:  2018-04-03       Impact factor: 3.240

4.  Effects of Sunitinib and Other Kinase Inhibitors on Cells Harboring a PDGFRB Mutation Associated with Infantile Myofibromatosis.

Authors:  Martin Sramek; Jakub Neradil; Petra Macigova; Peter Mudry; Kristyna Polaskova; Ondrej Slaby; Hana Noskova; Jaroslav Sterba; Renata Veselska
Journal:  Int J Mol Sci       Date:  2018-09-01       Impact factor: 5.923

5.  Actinomycin X2, an Antimicrobial Depsipeptide from Marine-Derived Streptomyces cyaneofuscatus Applied as a Good Natural Dye for Silk Fabric.

Authors:  Wei Chen; Kaixiong Ye; Xiaoji Zhu; Huihui Zhang; Ranran Si; Jianing Chen; Zijun Chen; Kaili Song; Zhicheng Yu; Bingnan Han
Journal:  Mar Drugs       Date:  2021-12-23       Impact factor: 5.118

6.  Genetic testing and surveillance in infantile myofibromatosis: a report from the SIOPE Host Genome Working Group.

Authors:  Simone Hettmer; Guillaume Dachy; Guido Seitz; Abbas Agaimy; Catriona Duncan; Marjolijn Jongmans; Steffen Hirsch; Iris Kventsel; Uwe Kordes; Ronald R de Krijger; Markus Metzler; Orli Michaeli; Karolina Nemes; Anna Poluha; Tim Ripperger; Alexandra Russo; Stephanie Smetsers; Monika Sparber-Sauer; Eveline Stutz; Franck Bourdeaut; Christian P Kratz; Jean-Baptiste Demoulin
Journal:  Fam Cancer       Date:  2020-09-05       Impact factor: 2.375

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.